GKB vs MOLBIO: Stock Comparison
Metric snapshot
GKB leads 0; MOLBIO leads 3 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | GKB | MOLBIO |
|---|---|---|
| Live Price | ₹65.6 | ₹1,307.4 |
| Day Change | 5.18% | 0.03% |
| Volume | 68 | 26.98 L |
| 52-Week High | ₹74 | ₹1,686.8 |
| 52-Week Low | ₹60.3 | ₹926.35 |
| Distance from 52W High | -11.35% | -22.49% |
Valuation
| Metric | GKB | MOLBIO |
|---|---|---|
| Market Cap | ₹0 Cr | ₹15,042 Cr |
| EPS | ₹-1 | ₹4.91 |
| Book Value | ₹108.89 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | GKB | MOLBIO |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -80.63% | -2.2% |
| Qtr Profit Growth | -127.19% | 7.36% |
Profitability & Leverage
| Metric | GKB | MOLBIO |
|---|---|---|
| Net Margin | 0% | 0% |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GKB | MOLBIO |
|---|---|---|
| Promoter Holding | 51.15%▲ 0.02 pp | 41.29% |
| FII Holding | 1.79% | 1.51% |
| DII Holding | 0% | 16.37% |
| Public Holding | 47.07%▼ 0.02 pp | 40.82% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GKB OPHTHALMICS and MOLBIO DIAGNOSTICS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.